Trials / Completed
CompletedNCT01399957
Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients
Responsiveness to Dalfampridine Treatment Among Multiple Sclerosis Patients Followed at the Mandell MS Center: Characterizing Clinical Predictors of Response and Identifying Additional Outcomes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Mount Sinai Rehabilitation Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staff will not be involved in any decisions to stop or start taking the medication.
Detailed description
Subjects will be evaluated before starting medication, throughout a 14week period after starting D-ER as well as at 12 and 18months following the start date of medication regardless of if they stayed on medication or not.
Conditions
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2014-09-01
- Completion
- 2015-09-01
- First posted
- 2011-07-22
- Last updated
- 2015-11-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01399957. Inclusion in this directory is not an endorsement.